Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sienna Biopharmaceuticals, Inc.SNNA · Entity 154554 | Director | May 30, 2019 | June 03, 2019 |
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Director · President and CEO | September 15, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sienna Biopharmaceuticals, Inc.
Report date May 30, 2019 · Filed June 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2029-05-30 | Direct | 25,000 |
Reported balance
After 2019-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-30 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date.
Tyra Biosciences, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,438,495 |
Reported balance
After 2026-09-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-15 · Grant · Acquired 864 · Balance 1,438,495 F1: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. F2: Includes restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.
F2: Includes restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2023 Filed Apr 5, 2023 21:20 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 2,000 | $2.25 | $4,500.00 |
DisclosureSEC source: 0001209191-23-023402 · doc4.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,703,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2023 Filed Mar 31, 2023 23:02 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001209191-23-021947 · doc4.xml · derivative · entry 9 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 399,537 Underlying: Common Stock · 500 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date. Read SEC document |
| March 31, 2023 Filed Mar 31, 2023 23:02 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 500 | $16.05 | $8,023.00 |
DisclosureSEC source: 0001209191-23-021947 · doc4.xml · nonDerivative · entry 6 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,701,276 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
| March 31, 2023 Filed Mar 31, 2023 23:02 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 500 | $2.25 | $1,125.00 |
DisclosureSEC source: 0001209191-23-021947 · doc4.xml · nonDerivative · entry 5 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,701,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2023 Filed Mar 31, 2023 23:02 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,407 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001209191-23-021947 · doc4.xml · derivative · entry 8 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,037 Underlying: Common Stock · 2,407 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date. Read SEC document |
| March 30, 2023 Filed Mar 31, 2023 23:02 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 2,407 | $16.02 | $38,551.96 |
DisclosureSEC source: 0001209191-23-021947 · doc4.xml · nonDerivative · entry 4 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,701,276 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
| March 30, 2023 Filed Mar 31, 2023 23:02 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 2,407 | $2.25 | $5,415.75 |
DisclosureSEC source: 0001209191-23-021947 · doc4.xml · nonDerivative · entry 3 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,703,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 23:02 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,420 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001209191-23-021947 · doc4.xml · derivative · entry 7 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402,444 Underlying: Common Stock · 1,420 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 23:02 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 1,420 | $16.18 | $22,980.57 |
DisclosureSEC source: 0001209191-23-021947 · doc4.xml · nonDerivative · entry 2 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,701,276 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 23:02 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 1,420 | $2.25 | $3,195.00 |
DisclosureSEC source: 0001209191-23-021947 · doc4.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,702,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 28, 2023 Filed Mar 28, 2023 23:09 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,779 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001209191-23-021443 · doc4.xml · derivative · entry 9 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 403,864 Underlying: Common Stock · 2,779 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date. Read SEC document |
| March 28, 2023 Filed Mar 28, 2023 23:09 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 2,779 | $16.00 | $44,464.00 |
DisclosureSEC source: 0001209191-23-021443 · doc4.xml · nonDerivative · entry 6 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,701,276 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
| March 28, 2023 Filed Mar 28, 2023 23:09 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 2,779 | $2.25 | $6,252.75 |
DisclosureSEC source: 0001209191-23-021443 · doc4.xml · nonDerivative · entry 5 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,704,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 27, 2023 Filed Mar 28, 2023 23:09 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,963 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001209191-23-021443 · doc4.xml · derivative · entry 8 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 406,643 Underlying: Common Stock · 2,963 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date. Read SEC document |
| March 27, 2023 Filed Mar 28, 2023 23:09 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 2,963 | $16.00 | $47,408.00 |
DisclosureSEC source: 0001209191-23-021443 · doc4.xml · nonDerivative · entry 4 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,701,276 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
| March 27, 2023 Filed Mar 28, 2023 23:09 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 2,963 | $2.25 | $6,666.75 |
DisclosureSEC source: 0001209191-23-021443 · doc4.xml · nonDerivative · entry 3 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,704,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 24, 2023 Filed Mar 28, 2023 23:09 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 170 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001209191-23-021443 · doc4.xml · derivative · entry 7 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 409,606 Underlying: Common Stock · 170 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date. Read SEC document |
| March 24, 2023 Filed Mar 28, 2023 23:09 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 170 | $16.00 | $2,720.00 |
DisclosureSEC source: 0001209191-23-021443 · doc4.xml · nonDerivative · entry 2 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,701,276 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
| March 24, 2023 Filed Mar 28, 2023 23:09 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 170 | $2.25 | $382.50 |
DisclosureSEC source: 0001209191-23-021443 · doc4.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,701,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2023 Filed Mar 23, 2023 23:49 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,800 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001209191-23-020848 · doc4.xml · derivative · entry 9 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 409,776 Underlying: Common Stock · 2,800 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date. Read SEC document |
| March 23, 2023 Filed Mar 23, 2023 23:49 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 2,800 | $16.00 | $44,800.00 |
DisclosureSEC source: 0001209191-23-020848 · doc4.xml · nonDerivative · entry 6 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,701,276 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
| March 23, 2023 Filed Mar 23, 2023 23:49 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 2,800 | $2.25 | $6,300.00 |
DisclosureSEC source: 0001209191-23-020848 · doc4.xml · nonDerivative · entry 5 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,704,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 23:49 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,043 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001209191-23-020848 · doc4.xml · derivative · entry 8 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 412,576 Underlying: Common Stock · 4,043 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 23:49 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 4,043 | $16.00 | $64,688.00 |
DisclosureSEC source: 0001209191-23-020848 · doc4.xml · nonDerivative · entry 4 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,701,276 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 23:49 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 4,043 | $2.25 | $9,096.75 |
DisclosureSEC source: 0001209191-23-020848 · doc4.xml · nonDerivative · entry 3 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,705,319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 23:49 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,393 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001209191-23-020848 · doc4.xml · derivative · entry 7 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,619 Underlying: Common Stock · 12,393 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 23:49 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 12,393 | $16.00 | $198,288.00 |
DisclosureSEC source: 0001209191-23-020848 · doc4.xml · nonDerivative · entry 2 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,701,276 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 23:49 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 12,393 | $2.25 | $27,884.25 |
DisclosureSEC source: 0001209191-23-020848 · doc4.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,713,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 21:28 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantCommon Stock | 1,808 | $6.58 | $11,894.83 |
DisclosureSEC source: 0001209191-23-019793 · doc4.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,701,276 F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 21:37 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 270,000 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001209191-22-049213 · doc4.xml · derivative · entry 2 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 270,000 shares Expires 2032-09-05 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following September 6, 2022, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| March 15, 2022 Filed Sep 8, 2022 21:37 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantCommon Stock | 3,125 | $8.53 | $26,642.19 |
DisclosureSEC source: 0001209191-22-049213 · doc4.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,699,468 F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:39 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 25,884 | $0.00 Strike: $24.15 | $0.00 |
DisclosureSEC source: 0001209191-21-063010 · doc4.xml · derivative · entry 3 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,884 Underlying: Common Stock · 25,884 shares Expires 2031-11-01 F2 · derivative.exercise_date: The option vests based on achievement of a performance objective. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:39 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 25,884 | $0.00 Strike: $24.15 | $0.00 |
DisclosureSEC source: 0001209191-21-063010 · doc4.xml · derivative · entry 2 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,884 Underlying: Common Stock · 25,884 shares Expires 2031-11-01 F2 · derivative.exercise_date: The option vests based on achievement of a performance objective. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:39 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 215,038 | $0.00 Strike: $24.15 | $0.00 |
DisclosureSEC source: 0001209191-21-063010 · doc4.xml · derivative · entry 1 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,038 Underlying: Common Stock · 215,038 shares Expires 2031-11-01 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following November 2, 2021, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:43 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionSeries A Preferred Stock · Derivative | 13,093 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036426 · doc4.xml · derivative · entry 2 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,007 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:43 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionCommon Stock | 34,007 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036426 · doc4.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,696,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 19:29 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 25,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001562180-19-003239 · primarydocument.xml · derivative · entry 1 Harris Todd · CIK 0001711463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-05-30 F1 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date. Read SEC document |
| April 30, 2018 Filed May 2, 2018 19:54 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | SaleCommon Stock | 100 | $20.00 | $2,000.00 |
DisclosureSEC source: 0001562180-18-002144 · primarydocument.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · Head of Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,991 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 22, 2017. Read SEC document |
| April 25, 2018 Filed Apr 25, 2018 19:21 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | SaleCommon Stock | 300 | $20.00 | $6,000.00 |
DisclosureSEC source: 0001562180-18-001976 · primarydocument.xml · nonDerivative · entry 3 Harris Todd · CIK 0001711463 · Director · Head of Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571,091 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 22, 2017. Read SEC document |
| April 24, 2018 Filed Apr 25, 2018 19:21 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | SaleCommon Stock | 150 | $20.00 | $3,000.00 |
DisclosureSEC source: 0001562180-18-001976 · primarydocument.xml · nonDerivative · entry 2 Harris Todd · CIK 0001711463 · Director · Head of Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571,391 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 22, 2017. Read SEC document |
| April 23, 2018 Filed Apr 25, 2018 19:21 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | SaleCommon Stock | 525 | $20.00 | $10,500.00 |
DisclosureSEC source: 0001562180-18-001976 · primarydocument.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · Head of Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571,541 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 22, 2017. Read SEC document |
| April 18, 2018 Filed Apr 19, 2018 18:00 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | SaleCommon Stock | 15,810 | $20.09 | $317,599.19 |
DisclosureSEC source: 0001140361-18-019087 · doc1.xml · nonDerivative · entry 2 Harris Todd · CIK 0001711463 · Director · Head of Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 572,066 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 22, 2017. F2 · price: This transaction was executed in multiple trades in prices ranging from $20.00 to $20.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 18:00 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | SaleCommon Stock | 2,201 | $20.00 | $44,020.00 |
DisclosureSEC source: 0001140361-18-019087 · doc1.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · Head of Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,876 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 22, 2017. Read SEC document |
| April 10, 2018 Filed Apr 12, 2018 18:45 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | SaleCommon Stock | 3,779 | $20.02 | $75,640.84 |
DisclosureSEC source: 0001140361-18-018411 · doc1.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · Head of Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,077 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 22, 2017. F2 · price: This transaction was executed in multiple trades in prices ranging from $20.00 to $20.22, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 09, 2018 Filed Apr 9, 2018 19:18 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | SaleCommon Stock | 2,824 | $20.00 | $56,480.00 |
DisclosureSEC source: 0001140361-18-017877 · doc1.xml · nonDerivative · entry 2 Harris Todd · CIK 0001711463 · Director · Head of Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,856 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 22, 2017. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 19:18 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | SaleCommon Stock | 5,386 | $20.00 | $107,725.39 |
DisclosureSEC source: 0001140361-18-017877 · doc1.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · Head of Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,680 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 22, 2017. F2 · price: This transaction was executed in multiple trades in prices ranging from $20.00 to $20.01, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 19:00 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | SaleCommon Stock | 5,876 | $20.00 | $117,520.00 |
DisclosureSEC source: 0001140361-18-014357 · doc1.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · Head of Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602,066 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 22, 2017. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:13 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | SaleCommon Stock | 3,452 | $20.11 | $69,429.04 |
DisclosureSEC source: 0001140361-18-013486 · doc1.xml · nonDerivative · entry 1 Harris Todd · CIK 0001711463 · Director · Head of Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 607,942 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 22, 2017. F2 · price: This transaction was executed in multiple trades in prices ranging from $20.00 to $20.73, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 09, 2018 Filed Mar 9, 2018 19:00 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | SaleCommon Stock | 2,438 | $20.01 | $48,784.14 |
DisclosureSEC source: 0001140361-18-012906 · doc1.xml · nonDerivative · entry 3 Harris Todd · CIK 0001711463 · Director · Head of Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 611,394 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 22, 2017. F3 · price: This transaction was executed in multiple trades in prices ranging from $20.00 to $20.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 19:00 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | SaleCommon Stock | 14,530 | $20.03 | $291,096.93 |
DisclosureSEC source: 0001140361-18-012906 · doc1.xml · nonDerivative · entry 2 Harris Todd · CIK 0001711463 · Director · Head of Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,832 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 22, 2017. F2 · price: This transaction was executed in multiple trades in prices ranging from $20.00 to $20.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.